Plain-English translation of NCT07313579 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is observing how a treatment called hyperthermic intraperitoneal chemoperfusion (HIPEC) works in patients with gastric cancer. During stomach removal surgery, doctors deliver heated chemotherapy directly into the abdominal cavity to try to eliminate any remaining cancer cells and prevent the cancer from spreading to the lining of the abdomen.
Standard surgery and chemotherapy alone don't always eliminate all cancer cells in advanced stomach cancer, especially when cancer has spread to the abdominal lining or shows signs of spreading there. This medication is being tested to see if delivering heat-enhanced chemotherapy directly where cancer is most likely to recur can improve outcomes.
You likely qualify if…
You likely don't qualify if…
If you enroll, you would undergo stomach removal surgery as planned. During that surgery, doctors would perform the heated chemotherapy treatment directly into your abdomen. After surgery, the research team would follow your progress and medical outcomes over time to see how well this combined approach works. The study involves 200 patients total and is being conducted in Ukraine by the Ukrainian Society of Clinical Oncology.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Ukraine
Sponsor
Ukrainian Society of Clinical Oncology
Enrollment target
~200 participants
Started
December 2025
Primary completion
December 2030
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Oleksiy Dobrzhanskyi, MD
Ukrainian Society of Clinical Oncology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.